Resultados globales: 1 registros encontrados en 0.03 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
8 p, 590.0 KB Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study / Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Hozak, Rebecca R (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Yoshino, Takayuki (Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan) ; Cohn, A. L. (Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA) ; Obermannova, R. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ; Bodoky, G. (St László Hospital (Hongria)) ; García-Carbonero, Rocío (Universidad Complutense de Madrid) ; Ciuleanu, Tudor Eliade (Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania) ; Portnoy, D. C. (Oncology, West Clinic, Memphis, USA) ; Prausová, J. (Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic) ; Muro, K. (Aichi Cancer Center Hospital) ; Siegel, R. W. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Konrad, R. J. (Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA) ; Ouyang, H. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Melemed, Symantha A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F. (Oncology, Eli Lilly and Company, Argentina) ; Van Cutsem, E. (KU Leuven, Leuven, Belgium) ; Universitat Autònoma de Barcelona
The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo + FOLFIRI as second-line metastatic colorectal cancer (mCRC) treatment. [...]
2017 - 10.1093/annonc/mdx767
Annals of oncology, Vol. 29 (december 2017) , p. 602-609  

Vea también: autores con nombres similares
1 Konrad, R. J.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.